Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients

European Journal of Clinical Pharmacology

Volumn 54, Issue 7, 1998, Pages 509-514

  Jonsson, E ^a   Fridborg, H ^a   Nygren, P ^a   Larsson, R ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytotoxicity assay; Human tumor cells; Topotecan

Indexed keywords

CISPLATIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; TOPOTECAN;

ARTICLE; CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; FLUOROMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DNA TOPOISOMERASES, TYPE I; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0031793524     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050505     Document Type: Article

References (24)

1. Takimoto C, Arbuck S (1996) The camptothecins. In: Chabner B, Longo D (eds) Cancer chemotherapy and biotherapy. Lippincott-Raven, Philadelphia, pp 463-484
2. Jonsson E, Fridborg H, Csóka K, Dhar S, Sundström C, Nygren P, Larsson R (1997) Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 76: 211-219
3. Dancey J, Eisenhauer E (1996) Current perspectives on camptothecins in cancer treatment. Br J Cancer 74: 327-338
4. Chou T, Motzer R, Tong Y, Bosi J (1994) Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524
5. Kaufmann S, Peereboom D, Buckwalter C, Svingen P, Grochow L, Donehower R, Rowinsky E (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88: 734-741
6. Weisenthal L (1991) Predictive assays for drug and radiation resistance. In: Masters J (ed) Human cancer in primary culture, a handbook. Kluwer Academic Publishers, Dordrecht, pp 103-147
7. Larsson R, Kristensen J, Sandberg C, Nygren P (1992) Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 50: 177-185
8. Larsson R, Nygren P (1990) Pharmacological modification of multi-drug resistance (MDR) in vitro detected by a novel fluorometric microculture cytotoxicity assay. Reversal of resistance and selective cytotoxic actions of cyclosporin A and verapamil on MDR leukemia T-cells. Int J Cancer 46: 67-72
9. Dhar S, Nygren P, Csóka K, Botling J, Nilsson K, Larsson R (1996) Anticancer drug characterization using a human cell line panel representing defined types of drug resistance. Br J Cancer 74: 888-896
10. Nygren P, Fridborg H, Csoka K, Sundström C, de la Torre M, Kristensen J, Bergh J, Hagberg H, Glimelius B, Rastad J, Tholander B, Larsson R (1994) Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer 56: 715-720
11. Larsson R, Fridborg H, Kristensen J, Sundström C, Nygren P (1993) In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukemia using the fluorometric microculture cytotoxicity assay (FMCA). Br J Cancer 67: 969-974
12. Kristensen J, Nygren P, Fridborg H, Killander A, Simonsson B, Öberg G, Larsson R (1994) Interactions between cladribine (2-chlorodcoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 8: 1712-1717
13. Csoka K, Larsson R, Tholander B, Gerdin E, de la Torre M, Nygren P (1994) Cytotoxic drug sensitivity testing of tumor cells from patients with ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA). Gynecol Oncol 54: 163-170
14. Nygren P, Kristensen J, Sundström C, Lönnerholm G, Kreuger A, Larsson R (1992) Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 11: 1121-1128
15. Valeriote F, Lin H (1975) Synergistic interaction of anticancer agents: a cellular perspective. Cancer Chemother Rep 59: 895-900
16. Sondak V, Korn E, Morton D, Kern D (1988) Testing chemotherapeutic combinations in the human tumor colony forming assay. J Surg Oncol 37: 156-160
17. Lepri E, Barzi A, Menconi E, Portuesi M, Liberati M (1991) In vitro synergistic activity of PDN-IFNα and NM + IFNα combinations on fresh bone-marrow samples from multiple myeloma patients. Hematol Oncol 9: 78-86
18. Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K (1992) Experimental studies on biochemical modulation targeting topoisomerase I and II in human xenografts in nude mice. Int J Cancer 50: 760-766
19. Bertrand R, O'Connor P, Kerrigan D, Pommier Y (1992) Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Fur J Cancer 28A: 743-748
20. Bonner J, Kozelsky T (1996) The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 39: 109-112
21. Lilenbaum R, Ratain M, Miller A, Hargis J, Hollis D, Rosner G, O'Brien S, Brewster L, Green M, Schilsky R (1995) Phase 1 study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study. J Clin Oncol 13: 2230-2237
22. Tolcher A, O'Shaughnessy J, Weiss R, Zujewski J, Myhand R, Schneider F, Hakim F, Gress R, Goldspiel B, Noone M, Brewster F, Gossard M, Cowan K (1997) Phase 1 study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 3: 755-761
23. Rowinsky E, Kaufmann S, Baker S, Grochow L, Chen T, Peereboom D, Bowling M, Sartorius S, Ettinger D, Forastiere A, Donehower R (1996) Sequences of topotecan and cisplatin: Phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol 14: 3074-3084
24. Beerenbaum M (1989) What is synergy? Pharmacol Rev 41: 93-132